Cardax (CDXI) Stock Price, News & Analysis

Company Overview

Cardax, Inc. is a development-stage biotechnology company focused on discovering and commercializing novel anti-inflammatory and immunomodulatory therapies. Headquartered in Port Townsend, Washington, the company applies a natural-product derivatization platform to modify astaxanthin, a carotenoid with well-documented antioxidant properties, into orally bioavailable drug candidates. These proprietary compounds are designed to target chronic inflammatory pathways that underlie a range of diseases.

Cardax’s research and development pipeline comprises multiple preclinical assets that have demonstrated efficacy in laboratory models of inflammatory and immune-mediated disorders. By esterifying astaxanthin, the company seeks to enhance solubility, tissue distribution and target engagement, with potential applications spanning cardiovascular health, joint inflammation and ocular disease. Cardax collaborates with contract research organizations and academic partners in the United States to advance its compounds toward clinical evaluation.

Operating as an OTC-listed issuer (OTCMKTS: CDXI), Cardax leverages a management team with expertise in drug development, natural product chemistry and pharmaceutical manufacturing. The company continues to build its scientific advisory capabilities in immunology and pharmacology as it prepares to initiate formal toxicology studies and, ultimately, human trials. Cardax remains focused on translating its unique chemistry platform into first-in-class treatments for patients with unmet needs in inflammatory diseases.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CDXI Stock Analysis - Frequently Asked Questions

How do I buy shares of Cardax?

Shares of CDXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardax investors own include Ashford Hospitality Trust (AHT), Peabody Energy (BTU), PlayAGS (AGS), Assertio (ASRT), Astronics (ATRO), CONSOL Coal Resources (CCR) and Alliance Resource Partners (ARLP).

Company Calendar

• Today: 7/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CDXI
• CIK: 1544238
• Web: www.cardaxpharma.com
• Phone: (808) 457-1400
• Fax: 808-237-5901
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 800,000
• Free Float: 566,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -1.49